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Even after optimal reperfusion strategies implementing percutaneous coronary 
intervention (PCI) with stent implantation and modern medical regimen for patients 
with acute myocardial infarction, myocardial salvage is often incomplete and adverse 
ventricular remodeling with subsequent heart failure develops. 
The transplantation of autologous bone marrow stem cells (BM-SCs) via the 
intracoronary delivery route after PCI of the infarct related artery (IRA) has been 
investigated in several observational studies which proved the safety and feasibility 
of the method.1 The results of the randomized studies were rather controversial. The 
BOOST study (Bone Marrow transfer to enhance ST-elevation infarction regeneration) 
was the first randomized study with patients receiving either bone-marrow derived 
mononuclear cells or placebo 5 days after primary PCI. The improvement of the ejec-
tion fraction reported in the cell infusion group at 6 months was attenuated during a 
follow-up study of 18 months. Of note, a similar restenosis rate (13%) was reported 
between the 2 groups.2
In the larger double-blind study (Reinfusion of Enriched progenitor Cells and 
Infarct Remodeling in Acute Myocardial Infarction, REPAIR-AMI), 204 patients 
were randomized in 2 groups, one receiving bone-marrow derived mononuclear cells 
intracoronarilly and the other receiving placebo infusion.3,4 At 4 months, left ven-
tricular ejection fraction improved significantly in the cell treated group. This group 
also showed greater clinical benefit during a follow-up of 12 months regarding death, 
myocardial infarction, revascularization and re-hospitalization for heart failure. 
In a recent study from Lunde et al5 (Autologous Stem-Cell Transplantation in acute 
Myocardial Infarction, ASTAMI), patients were randomized to either intracononary 
cell infusion or placebo 6 days after primary PCI for anterior myocardial infarction. 
Six months later echocardiography, SPECT and MRI revealed no difference in left 
ventricular volumes, ejection fraction or infarct size between the 2 groups. 
Janssens et al6 randomized patients early after acute myocardial infarction (within 
the first 24 hours) into intracoronary cell delivery or placebo. The cell treated group 
showed an improvement in perfusion and regional contractility, but no difference was 
noted in the increase of the global ejection fraction between the 2 groups. 
Based on the knowledge that bone marrow-derived progenitor cells can reach the 
target organ through peripheral blood and that tissue repair is mediated by cytokines 
secreted from sites of ischemic injury an effort was made to evaluate the enhancement 
of this natural repair mechanism by exogenous delivery of G-CSF (Granulocyte-colony-
stimulating-factor) and/or other cytokines on cardiac repair.7 
In the MAGIC trial (Myocardial Regeneration and Angiogenesis in Myocardial 
Infarction With G-CSF and Intracoronary Stem Cell Infusion)8, Kang et al delivered 
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G-CSF subcutaneously starting 4 days before PCI for patients 
with acute and remote myocardial infarction. Even though 
there was a favorable effect of the mobilization of the stem/
progenitor cells on the improvement of left ventricular ejection 
fraction and regional perfusion, the study was terminated pre-
maturely because of the high incidence of increased restenosis 
rate in the group treated with G-CSF. The intracoronary 
transplantation of G-CSF mobilized peripheral blood stem 
cells vs an untreated control group was studied in the subse-
quent MAGIC Cell-3-DES study. Two patient groups were 
studied after being treated with PCI and drug eluting stents 
after myocardial infarction. This study showed an improve-
ment in left ventricular dimensions and ejection fraction, but 
most importantly no increased restenosis rate was noted.
In the FIRSTLINE-AMI10,11 study from Ince et al, 25 
patients received G-CSF approximately 0 minutes after 
primary PCI for acute myocardial infarction. The cardiac 
function (regional and global ejection fraction, left ventricular 
dimensions and viability) increased significantly in the G-
CSF group compared to the control group and there were no 
adverse events noted, including restenosis.
The recent study REVIVAL-212 by Zohlnhofer was a 
double-blind study with 114 patients, who were randomized 
to subcutaneous delivery of G-CSF for 5 days after primary 
PCI or placebo. At 4-6 months there was no difference in 
the reduction of the infarct size and improvement of the left 
ventricular ejection fraction between the 2 groups.
In conclusion, even though the exact mechanism of cell 
transplantation still remains unclear, small observational clini-
cal studies have shown the feasibility and safety of the method 
in patients treated with primary PCI and stent implantation 
of the IRA after acute myocardial infarction. The results of 
the recent randomized clinical trials were rather controversial 
regarding the effects of the intracoronarilly delivered bone 
marrow-derived stem cells or G-CSF mobilized bone marrow 
stem/progenitor cells on cardiac performance, dimensions and 
perfusion of the infarcted area. Further large, double-rand-
omized, controlled trials are needed in order to establish the 
efficacy and possible role of cell therapy in the management 
patients in the early post-infarction period.
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